Uprety Dipesh, Parikh Kaushal, Sawkar Anita, Dimou Anastasios, Leventakos Konstantinos
Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Department of Oncology, Hackensack University Medical Center, Hackensack, NJ, USA.
J Thorac Dis. 2020 Nov;12(11):6992-7001. doi: 10.21037/jtd-20-1472.
Lung cancer is the most common cancer worldwide. Approximately 18% of all deaths related to cancer are associated with lung cancer. Management of non-small cell lung cancer (NSCLC) has been changing rapidly in last few years. For patients with unresectable non-metastatic disease, maintenance durvalumab is now given after offering chemo-radiation concurrently based on the result from the PACIFIC trial. Management of metastatic disease greatly depends on the status of sensitizing driver mutation and PD-L1 level of the tumor cells. In this review article, we will summarize the outcome of various clinical trials and will provide the most up-to-date information on the management of patients with advanced and metastatic NSCLC.
肺癌是全球最常见的癌症。所有癌症相关死亡中约18%与肺癌有关。在过去几年中，非小细胞肺癌（NSCLC）的治疗方法一直在迅速变化。对于不可切除的非转移性疾病患者，根据PACIFIC试验的结果，现在在同步进行放化疗后给予度伐利尤单抗维持治疗。转移性疾病的治疗很大程度上取决于肿瘤细胞的敏感驱动基因突变状态和PD-L1水平。在这篇综述文章中，我们将总结各种临床试验的结果，并提供有关晚期和转移性NSCLC患者治疗的最新信息。
Zotero 插件